Khảo sát thuốc ức chế men dpp-4 trên bệnh nhân đái tháo đường týp 2 điều trị ngoại trú tại Bệnh viện Đa khoa trung ương Cần Thơ=Survey of dpp-4 enzyme inhibitors on type 2 diabetes patients treated as outpatients at Can Tho central general hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Thu Hồng Giang, Thị Tố Quyên Lâm, Hiền Việt Anh Nguyễn, Thị Huyền Trang Phạm

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học và Kinh tế Phát triển (Trường Đại học Nam Cần Thơ), 2024

Mô tả vật lý: tr.110-116

Bộ sưu tập: Báo, Tạp chí

ID: 156717

Thêm vào giỏ

Đái tháo đường týp 2 là bệnh lý thường gặp. Thuốc ức chế dipeptidyl peptidase 4 (DPP-4) là nhóm thuốc điều trị đái tháo đường và giúp bệnh nhân có thêm lựa chọn trong trong điều trị đái tháo đường týp 2. Khảo sát thuốc ức chế DPP-4 trên bệnh nhân đái tháo đường typ 2 điều trị ngoại trú tại bệnh viện đa khoa Trung Ương cần Thơ. Nghiên cứu mô tả cắt ngang trên 108 bệnh nhân đái tháo đường týp 2 chưa đạt mục tiêu HbAlc (HbAlc >
7%), được chỉ định thuốc ức chế DPP-4 lần đầu tiên và không thay đổi phác đồ đái tháo đường trong 3 tháng khảo sát. Thông tin được thu thập từ hồ sơ điều trị ngoại trú. Các dữ liệu được xử lý bằng phần mềm IBM SPSS 22.0 để tính tỷ lệ, so sánh kết quả. Thuốc ức chế DPP-4 được chỉ định nhiều nhất là sitagliptin. Metformin là thuốc được chỉ định phối hợp nhiều nhất với thuốc ức chế DPP-4. Sau 3 tháng khảo sát, glucose huyết giảm trung bình 1,64 ± 1,59 (mmol/L) và HbAlc giảm trung bình 1,52 ± 1,17%
53,7%) bệnh nhân đạt mục tiêu glucose huyết và 47,2% bệnh nhân đạt mục tiêu HbAlc. Tỷ lệ bệnh nhân gặp tương tác trong đơn là 23,5% chủ yếu gặp ở metformin và insulin. Hiệu quả của việc sử dụng thuốc ức chế DPP-4 trên bệnh nhân đái tháo đường týp 2 chưa kiểm soát tốt HbAlc đã được ghi nhận trong nghiên cứu. Mặc dù glucose huyết và HbAlc giảm sau 3 tháng điều trị với thuốc ức chế DPP4 nhưng tỷ lệ đạt mục tiêu điều trị vẫn chưa cao.Type 2 diabetic is a common situation. Dipeptidyl peptidase- 4 inhibitor is a class of drugs to treat diabetes mellitus and give patients more options in the treatment of type 2 diabetes. To investigate the use of DPP-4 inhibitors among type 2 diabetic outpatients at Can Tho central general hospital. A descriptive cross-sectional study was conducted in 108 patients with type 2 diabetes mellitus who had not reached the HbAlc target (HbAlc >
7%) and indicated DPP-4 inhibitors for the first time without changing the regimen for 3 months. Data was collected f-rom medical records. The most popular DPP-4 inhibitor prescribed was sitagliptin. Metformin was the most common oral hypoglycemic agent to be combined with DPP-4 inhibitors. After 3 months under treatment with DPP-4 inhibitors, blood glucose level reduced by 1,64 ± 1,59 mmol/L, HbAlc reduced by 1,52 ± 1,17% on average
53,7% and 47,2% of the study population achieved blood glucose goal and HbAlc goal, respectively. The percentage of patients experiencing interactive application is primarily seen in 23.5% metformin and insulin. The use of DPP 4 inhibitors in patients with type 2 diabetes mellitus who had not reached the HbAlc goal was found to be effective. Although the change in blood glucose and HbAlc was significant, the proportion of patients reaching treatment goals was still below expectation.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR